SOURCE: Entest BioMedical Inc.

January 05, 2011 10:00 ET

Entest BioMedical Announces the Completion of the McDonald Animal Hospital Acquisition

Entest Sees Immediate Revenue as the New Year Gets Underway

Company Has Already Identified Several Other Candidates to Pursue as It Rolls Out Its Business Model

SAN DIEGO, CA--(Marketwire - January 5, 2011) - Entest BioMedical Inc. (OTCBB: ENTB) announced today it has completed the acquisition of the McDonald Animal Hospital (MAH) in Santa Barbara, California. Entest officially took control of MAH yesterday, January 4, 2011.

Entest BioMedical's Chairman & CEO David Koos stated, "All of us associated with this transaction are extremely excited about McDonald Animal Hospital joining the Entest family. We feel that the addition of high quality professionals such as Dr. Gregory McDonald and the MAH staff will play an important role in achieving our goal of becoming a strong player in the veterinary sector as well as the biotechnology sector."

Mr. Koos further noted, "With the acquisition of the McDonald Animal Hospital, we gain a relationship that is both revenue producing and a conduit for our veterinary therapies. Additionally, Dr. McDonald represents a strong clinical resource to Entest as we develop our immuno-therapeutic cancer vaccine for dogs -- ImenVax™."

A spokesperson for Entest BioMedical Inc. stated the acquisition of the McDonald Animal Hospital represents the first of several anticipated acquisitions by the company. Initially, Entest plans on focusing on veterinary acquisition candidates in California, with future plans to expand into other states.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information